Pharmacological treatment of neurodegenerative disorders, amyotrophic lateral sclerosis and duchenne muscular dystrophy
Absztrakt
Neurodegenerative disorders are characterized by a gradual dysfunction and loss of neurons and axon in the central nervous system. The clinical features of this diverse group of neurological disorders depend on the particular central nervous system regions involved. The two most common neurodegenerative disorders are Alzheimer’s disease and Parkinson’s disease, after that are amyotrophic lateral sclerosis and Huntington disease. Despite of the increasing prevalence and many efforts of researchers, neurodegeneration disorders still remain mysterious in many aspects which causes many difficulties in clinical approach for treating these diseases. Till date, there’s no definite treatments that can stop or reverse the course of these, so for the time being, we all depend on palliative care to preserve cognitive functions as well as treatment for behavioral changes Duchenne Muscular Dystrophy is a progressive and lethal disease caused by mutations of the dystrophin gene. Currently, DMD is mainly managed with multidisciplinary symptomatic treatment focus on treatment with glucocorticoids and physiotherapy to prevent orthopedic complications.